The Glutaminyl Peptide Cyclotransferase pipeline drugs market research report outlays comprehensive information on the Glutaminyl Peptide Cyclotransferase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Glutaminyl Peptide Cyclotransferase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, Gastrointestinal, and Mouth and Dental Disorders which include the indications Unspecified Cancer, Oncology, Alzheimer’s Disease, Huntington Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Periodontal Disease, and Periodontitis. It also reviews key players involved in Glutaminyl Peptide Cyclotransferase targeted therapeutics development with respective active and dormant or discontinued products.
The Glutaminyl Peptide Cyclotransferase pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 3, and 2 respectively.
Glutaminyl Peptide Cyclotransferase overview
Glutaminyl Peptide Cyclotransferase is an enzyme that in humans is encoded by a gene QPCT. This enzyme is involved in the post-translational modification of proteins. Majorly QPCT catalyzes the cyclization of N-terminal glutamine residues to form pyroglutamate. This modification is a common post-translational alteration in peptides and proteins. Dysregulation of QPCT activity or the accumulation of pyroglutamate-modified proteins has been associated with certain diseases, including neurodegenerative disorders such as Alzheimer’s disease. In Alzheimer’s disease, the formation of pyroglutamate-modified forms of amyloid-beta peptides has been observed.
For a complete picture of Glutaminyl Peptide Cyclotransferase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
